AMPLIFON SPA: directors' dealings · Italy · Consob

About AMPLIFON SPA

Amplifon S.p.A. is a global leader in retail hearing care, listed on Borsa Italiana (FTSE MIB) in Italy. The company was founded in Milan in 1950 by Algernon Charles Holland, originally with a social mission in the post-war period: to provide hearing solutions to people affected by war-related sound damage. Over time, Amplifon evolved from a local specialist into an international hearing-care platform focused on the assessment, fitting, distribution and long-term support of hearing aids and related services. Its global headquarters are in Milan, which also serves as the center for strategy, innovation and corporate governance. Amplifon’s business model is built around a dense retail network of hearing-care centers, operated both directly and through franchising in some markets, combined with a highly personalized customer journey. The group offers hearing aids, accessories, audiological testing, tailor-made fitting services, aftercare, and digital tools that support patient engagement and follow-up. This product-and-service mix is central to Amplifon’s competitive positioning, because hearing care is a trust-based category where clinical expertise, local presence, service quality and retention matter as much as the device itself. The company describes itself as the world leader in retail hearing care, with a global market share of around 13% in its corporate communications. It operates in 25 countries, with nearly 10,000 hearing-care centers and more than 20,000 employees, giving it a broad footprint across Europe, North America, Australia and parts of Latin America. This geographic diversification reduces reliance on any single national market and supports a more resilient long-term growth profile. Strategically, Amplifon emphasizes innovation, customer experience and digitalization, including proprietary tools and omnichannel services designed to improve access, diagnostics and ongoing care. Recent milestones include 2025 consolidated revenues of about €2.4 billion and the launch of the Fit4Growth plan, which aims to strengthen profitability and competitiveness through 2027. In early 2026, the company reported faster organic growth, a record adjusted EBITDA margin for the quarter, and further investments in audiological research and innovation. For investors, Amplifon remains a structurally attractive healthcare-related franchise benefiting from demographic trends, aging populations and the increasing prevalence of hearing-loss awareness, while operating from Italy within the FTSE MIB universe.